Close Menu

NEW YORK – GenMark Diagnostics reported after the close of the market on Tuesday a 118 percent increase in second quarter revenues, driven by COVID-19 testing sales.

The Carlsbad, California-based molecular diagnostics firm reported $40.1 million in revenue, up from $18.4 million in Q2 of 2019 and beating the consensus analyst estimate of $32.7 million.

The firm booked ePlex revenues of $35.2 million for the quarter, representing 195 percent growth over the prior-year quarter, with average annuity per analyzer up 74 percent to $188,000.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.